B-cell Malignancies
📧 Sign up to get email alerts when something new happens for B-cell Malignancies.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies [Phase 1]
Phase 1 study of INCB040093 in subjects with previously treated B-cell malignancies; the trial is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies [Phase 1]
This is a Phase 1 dose-escalation and dose-expansion study of tirabrutinib in combination with other targeted therapies for adults with B-ce…
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) [Phase 1]
The COBALT-LYM Phase 1 trial evaluating CTX130 in relapsed or refractory T- or B-cell malignancies has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-11-27Clinical Trial Update: Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies [Phase 1]
Phase 1 trial evaluating pharmacokinetic interactions between zanubrutinib and moderate/strong CYP3A inhibitors in participants with B-cell …
-
CLINICAL_TRIALS trial_result · 2023-07-13Clinical Trial Update: Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects [Phase 1, Phase 2]
Phase I/II trial update for TL-895 with navtemadlin in treatment-naïve and relapsed/refractory B cell malignancies, including CLL/SLL and re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) [Phase 1, Phase 2]
Phase 1/2 study evaluating Epacadostat in combination with Nivolumab in select advanced cancers; results have been posted following completi…
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) [Phase 1, Phase 2]
Phase 1/2 open-label dose-escalation trial evaluating INCB050465 and itacitinib in previously treated B-cell malignancies; study completed w…
-
CLINICAL_TRIALS trial_result · 2022-03-24Clinical Trial Update: Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
Phase 1 trial updates long-term safety and efficacy of tirabrutinib in adults with relapsed/refractory B-cell malignancies; study completed …
-
CLINICAL_TRIALS trial_result · 2020-05-13Clinical Trial Update: A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies [Phase 1, Phase 2]
Clinical study of MEDI-551 in adults with relapsed or refractory advanced B-cell malignancies completed; results posted.
-
CLINICAL_TRIALS trial_result · 2017-04-10Clinical Trial Update: A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies [Phase 1]
This phase 1 dose-escalation study evaluated MEDI-551 (inebilizumab) in Japanese adults with relapsed or refractory advanced B-cell malignan…
-
CLINICAL_TRIALS trial_result · 2013-12-10Clinical Trial Update: A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation [Phase 1]
A Phase I study evaluating WT1 peptide immunotherapy to induce anti-leukemia immune responses after transplantation was terminated.